Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21698646 | 0.97 | CYP11B2 (0.67) | CYP11B2 | |
| SCHEMBL21698786 | 0.97 | CYP11B2 (0.67) | CYP11B2 | |
| SCHEMBL23128878 | 0.92 | CYP11B2 (0.64) | CYP11B2 | |
| SCHEMBL23128857 | 0.92 | CYP11B2 (0.64) | CYP11B2 | |
| SCHEMBL21831949 | 0.88 | CYP11B2 (0.67) | CYP11B2 | |
| SCHEMBL21831948 | 0.88 | CYP11B2 (0.67) | CYP11B2 | |
| SCHEMBL21832029 | 0.83 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL21832014 | 0.82 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL21831998 | 0.77 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL23128895 | 0.76 | CYP11B2 (0.56) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-09-13 | — | — | US | disclosed |
| US-20200347067-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-11-05 | — | — | US | disclosed |
| US-20200347067-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-11-05 | — | — | US | disclosed |
| WO-2020223469-A1 | N-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)-4,5-DI HYDRO-1H-IMIDAZO[4,5-H]QUINAZOLIN-8-AMINE DERIVATIVES AND RELATED COMPOUNDS AS CYCLIN-DEPENDENT KINASE 2 (CDK2) INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020223469-A1 | N-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)-4,5-DI HYDRO-1H-IMIDAZO[4,5-H]QUINAZOLIN-8-AMINE DERIVATIVES AND RELATED COMPOUNDS AS CYCLIN-DEPENDENT KINASE 2 (CDK2) INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
| EP-3608321-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | CDK4, CDK2, CDKL1 | CYP11B2 3436/4885 |
| US-20200347067-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | CYP11B2 2473/4885 |
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | CDK2, CDK1, CCNI | CYP11B2 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.